Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Monte Rosa Therapeutics (GLUE) Net Margin: 2024-2025

Historic Net Margin for Monte Rosa Therapeutics (GLUE) over the last 2 years, with Sep 2025 value amounting to -212.10%.

  • Monte Rosa Therapeutics' Net Margin rose 4679.00% to -212.10% in Q3 2025 from the same period last year, while for Sep 2025 it was 11.52%, marking a year-over-year change of. This contributed to the annual value of -96.18% for FY2024, which is N/A change from last year.
  • Monte Rosa Therapeutics' Net Margin amounted to -212.10% in Q3 2025, which was down 300.12% from -53.01% recorded in Q2 2025.
  • Monte Rosa Therapeutics' 5-year Net Margin high stood at 55.20% for Q1 2025, and its period low was -3,006.11% during Q1 2024.
  • Moreover, its 2-year median value for Net Margin was -212.10% (2025), whereas its average is -585.48%.
  • Data for Monte Rosa Therapeutics' Net Margin shows a peak YoY soared of 306,131bps (in 2025) over the last 5 years.
  • Quarterly analysis of 2 years shows Monte Rosa Therapeutics' Net Margin stood at 22.11% in 2024, then skyrocketed by 4,679bps to -212.10% in 2025.
  • Its Net Margin stands at -212.10% for Q3 2025, versus -53.01% for Q2 2025 and 55.20% for Q1 2025.